Morningstar

Ensoma to Present Preclinical Data and Manufacturing Advancements for In Vivo HSC Engineering Platform to Treat Cancer, Immune Disorders and Genetic Diseases at ASGCT 28th ...

“We look forward to presenting preclinical data at ASGCT that underscore the potential of our in vivo HSC engineering platform to address complex genetic disorders and cancer,” said Robert Peters, ...
Business Wire

Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline

BOSTON--(BUSINESS WIRE)--Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company with a mission to advance the future of medicine through one-time therapies, today announced the closing ...
Labroots

Monoclonality Assurance Using CloneSelect Single-Cell Printer and CloneSelect Imager in Human Stem Cell (hSC) Engineering Workflow

In recent years regenerative cell therapy utilizing the pluripotency of hESCs or iPSCs is gaining its ground and holds promise to outpace conventional treatment options for cardiac, kidney, liver, ...
Morningstar

Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline

Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline Company’s Phase 1/2 Clinical ...
Seeking Alpha

Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline

Company’s Phase 1/2 Clinical Trial of EN-374 in X-linked Chronic Granulomatous Disease is Now Open for Patient Enrollment BOSTON--(BUSINESS WIRE)-- Ensoma, an in vivo hematopoietic stem cell (HSC) ...